NCI Debuts New Program for Cancer Advocates

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 4
Volume 10
Issue 4

BETHESDA, Md-The National Cancer Institute has opened its arms wider to the advocacy community with a new program called Consumer Advocates in Research and Related Activities, or CARRA. NCI plans to recruit 150 consumer advocates under the CARRA program who will serve 3-year terms. The advocates are to represent survivors’ concerns, provide their ideas and viewpoints directly to the NCI staff, and serve as links between the advocacy communities and the Institute.

BETHESDA, Md—The National Cancer Institute has opened its arms wider to the advocacy community with a new program called Consumer Advocates in Research and Related Activities, or CARRA. NCI plans to recruit 150 consumer advocates under the CARRA program who will serve 3-year terms. The advocates are to represent survivors’ concerns, provide their ideas and viewpoints directly to the NCI staff, and serve as links between the advocacy communities and the Institute.

CARRA advocates must be cancer survivors, or a family member or life partner of a person with cancer, or have been involved for 3 years or more in cancer activities. CARRA applications are available at http://liaison.cancer.gov/CARRA.

Articles in this issue
IOM Urges Action to Fix ‘Broken’ US Health Care System
Thompson Pledges Fundamental HCFA Reform
NCCN Updates Its Practice Guideline for Breast Cancer
Smoking Prevalence, Mortality Ranges Widely From State to State
NCI Debuts New Program for Cancer Advocates
Fiberoptic Ductoscopy for Nipple Discharge DisWomen With Nipple Discharge
Augmerosen, Antisense Drug, in Phase III Testing in Melanoma
Automated System Improves Accuracy of HER-2 Scoring
Small Advantage for Adjuvant Paclitaxel in Early Breast Cancer
New HIV Guidelines Lower the Count for Starting Therapy Antiretroviral Therapy
Prostate Cancer Research at UCSF Focuses on Dendritic Cells
Pretransplant Mylotarg Boosts Survival in Relapsed AML
Thalidomide Demonstrates Multiple Roles in Myeloma
DepoCyt, Liposomal Cytarabine, Reintroduced Into US Market
Film Mammography Still the Gold Standard: IOM Report
Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content
According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.

The Paradigm of AML Care: What’s New and What’s Changing

Tim Cortese
November 30th 2025
Article

According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC

HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC

Ariana Pelosci
November 29th 2025
Article

HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.